0000947871-23-000778.txt : 20230724
0000947871-23-000778.hdr.sgml : 20230724
20230724164042
ACCESSION NUMBER: 0000947871-23-000778
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230720
FILED AS OF DATE: 20230724
DATE AS OF CHANGE: 20230724
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Gupta Rishi
CENTRAL INDEX KEY: 0001537370
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41747
FILM NUMBER: 231105501
MAIL ADDRESS:
STREET 1: C/O CHEMOCENTRYX, INC.
STREET 2: 850 MAUDE AVENUE
CITY: MOUNTAIN VIEW
STATE: CA
ZIP: 94043
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Turnstone Biologics Corp.
CENTRAL INDEX KEY: 0001764974
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 832909368
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 920 BROADWAY
STREET 2: 16TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10010
BUSINESS PHONE: 347-897-5988
MAIL ADDRESS:
STREET 1: 920 BROADWAY
STREET 2: 16TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10010
4
1
ownership.xml
X0508
4
2023-07-20
0
0001764974
Turnstone Biologics Corp.
TSBX
0001537370
Gupta Rishi
C/O TURNSTONE BIOLOGICS CORP.
9310 ATHENA CIRCLE, SUITE 300
LA JOLLA
CA
92037
1
0
1
0
0
Common Stock
2023-07-20
4
C
0
2682599
A
2682599
I
See Footnote
Common Stock
2023-07-20
4
P
0
416666
12
A
3099265
I
See Footnote
Series B-1 Preferred Stock
2023-07-20
4
C
0
937372
D
Common Stock
937372
0
I
See Footnotes
Series B-2 Preferred Stock
2023-07-20
4
C
0
1249829
D
Common Stock
1249829
0
I
See Footnotes
Series C Preferred Stock
2023-07-20
4
C
0
266240
D
Common Stock
266240
0
I
See Footnotes
Series D Preferred Stock
2023-07-20
4
C
0
229158
D
Common Stock
229158
0
I
See Footnotes
Each share of Series B-1 Preferred Stock, Series B-2 Preferred Stock, Series C Preferred Stock, and Series D Preferred Stock automatically converted into shares of the Issuer's common stock on a one-to-one basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date.
These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI, and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VI. The Reporting Person is an employee of OrbiMed Advisors. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VI and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VI.
Each of the Reporting Person, OrbiMed Advisors and GP VI disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, GP VI, or OrbiMed Advisors is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
/s/ Rishi Gupta
2023-07-24